SCHEMBL10243624

SCHEMBL10243624

CCN(CCNC(=O)OC)C(C)c1cccc(N)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 5/20 0.37
BCHE P06276 3/20 0.37
FAAH O00519 1/20 0.37
CPN1 P15169 1/20 0.36
CPB2 Q96IY4 1/20 0.36
MARK4 Q96L34 1/20 0.35
LMNA P02545 2/20 0.35
ALDH1A1 P00352 2/20 0.35
SLC22A2 O15244 1/20 0.35
SLC22A1 O15245 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
CYP2C19 P33261 1/20 0.35
ADRB3 P13945 2/20 0.35
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35
MTNR1A P48039 2/20 0.35
MTNR1B P49286 2/20 0.35
BLM P54132 1/20 0.34
PMP22 Q01453 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243821 0.87 OPRK1 (0.46) ACHEBCHEFAAHLMNASLC22A1
SCHEMBL10244077 0.87 CYP2C19 (0.42) ACHEBCHEFAAHMARK4ALDH1A1
SCHEMBL10243869 0.86 BCHE (0.37) ACHEBCHEFAAHALDH1A1CYP2C19
SCHEMBL10243833 0.86 CYP2C19 (0.43) ACHEBCHEFAAHTSHRCYP2C19
SCHEMBL10244397 0.86 MTNR1A (0.47) ACHEBCHEFAAHMTNR1AMTNR1B
SCHEMBL10243444 0.86 RAB9A (0.45) LMNAALDH1A1TSHRMAPK1CYP2C19
SCHEMBL10243429 0.86 MTNR1A (0.47) ACHEBCHEFAAHMTNR1AMTNR1B
SCHEMBL10243851 0.86 MTNR1A (0.47) ACHEBCHEFAAHMTNR1AMTNR1B
SCHEMBL10243497 0.85 SLC22A1 (0.43) LMNAALDH1A1SLC22A1MTNR1AMTNR1B
SCHEMBL10243668 0.85 MTNR1A (0.39) ACHEBCHEFAAHMARK4MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 ACHE 1324/4885BCHE 1393/4885FAAH 4386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.